- Home
- BOOT vs OGN Comparison
BOOT vs OGN Comparison
Compare BOOT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- OGN
- Stock Information
- Founded
- BOOT 1978
- OGN 1923
- Country
- BOOT United States
- OGN United States
- Employees
- BOOT N/A
- OGN N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- BOOT Consumer Discretionary
- OGN Health Care
- Exchange
- BOOT Nasdaq
- OGN Nasdaq
- Market Cap
- BOOT 4.4B
- OGN 4.0B
- IPO Year
- BOOT 2014
- OGN N/A
- Fundamental
- Price
- BOOT $151.61
- OGN $15.10
- Analyst Decision
- BOOT Strong Buy
- OGN Hold
- Analyst Count
- BOOT 11
- OGN 3
- Target Price
- BOOT $164.36
- OGN $21.33
- AVG Volume (30 Days)
- BOOT 638.3K
- OGN 2.9M
- Earning Date
- BOOT 01-29-2025
- OGN 02-13-2025
- Dividend Yield
- BOOT N/A
- OGN 7.65%
- EPS Growth
- BOOT N/A
- OGN 120.97
- EPS
- BOOT 4.98
- OGN 5.04
- Revenue
- BOOT $1,758,043,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- BOOT $15.96
- OGN $3.11
- Revenue Next Year
- BOOT $14.07
- OGN $2.55
- P/E Ratio
- BOOT $30.10
- OGN $2.93
- Revenue Growth
- BOOT 3.51
- OGN 4.21
- 52 Week Low
- BOOT $68.37
- OGN $13.14
- 52 Week High
- BOOT $169.83
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- BOOT 55.53
- OGN 42.91
- Support Level
- BOOT $143.58
- OGN $14.53
- Resistance Level
- BOOT $151.48
- OGN $15.41
- Average True Range (ATR)
- BOOT 5.03
- OGN 0.52
- MACD
- BOOT 0.60
- OGN 0.02
- Stochastic Oscillator
- BOOT 61.37
- OGN 31.89
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.